The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Kyntheum brodalumab | LEO Pharma A/S | Psoriasis | 🇪🇺 EU 2017-07-17 | Order → |
| Trimbow beclometasone;formoterol;glycopyrronium bromide | Chiesi Farmaceutici S.p.A. | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2017-07-17 | Order → |
| Blitzima rituximab Biosimilar | Celltrion Healthcare Hungary Kft. | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | 🇪🇺 EU 2017-07-13 | Order → |
| Reagila cariprazine | Gedeon Richter | Schizophrenia | 🇪🇺 EU 2017-07-13 | Order → |
| Ritemvia rituximab BiosimilarAdditional monitoring | Celltrion Healthcare Hungary Kft. | Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Wegener Granulomatosis | 🇪🇺 EU 2017-07-13 | Order → |
| Rituzena (previously Tuxella) rituximab BiosimilarAdditional monitoring | Celltrion Healthcare Hungary Kft. | Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Wegener Granulomatosis | 🇪🇺 EU 2017-07-13 | Order → |
| Spherox spheroids of human autologous matrix-associated chondrocytes ATMP | CO.DON Gmbh | Cartilage Diseases | 🇪🇺 EU 2017-07-10 | Order → |
| Oxervate cenegermin OrphanAccelerated assessment | Dompe' Farmaceutici S.p.A. | Keratitis | 🇪🇺 EU 2017-07-06 | Order → |
| Besponsa inotuzumab ozogamicin Orphan | Pfizer Europe MA EEIG | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU 2017-06-28 | Order → |
| Erelzi etanercept Biosimilar | Sandoz GmbH | Arthritis, Psoriatic; Psoriasis; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid; Spondylitis, Ankylosing | 🇪🇺 EU 2017-06-23 | Order → |
| Kevzara sarilumab Additional monitoring | Sanofi Winthrop Industrie | Arthritis, Rheumatoid | 🇪🇺 EU 2017-06-23 | Order → |
| Skilarence dimethyl fumarate | Almirall, S.A. | Psoriasis | 🇪🇺 EU 2017-06-23 | Order → |
| Ucedane carglumic acid Generic | Eurocept International BV | Hyperammonemia; Amino Acid Metabolism, Inborn Errors | 🇪🇺 EU 2017-06-23 | Order → |
| Febuxostat Viatris (previously Febuxostat Mylan) febuxostat Generic | Viatris Limited | Hyperuricemia; Arthritis, Gouty; Gout | 🇪🇺 EU 2017-06-15 | Order → |
| Rixathon rituximab Biosimilar | Sandoz GmbH | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Wegener Granulomatosis; Microscopic Polyangiitis; Pemphigus | 🇪🇺 EU 2017-06-15 | Order → |
| Riximyo rituximab Biosimilar | Sandoz GmbH | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis; Wegener Granulomatosis | 🇪🇺 EU 2017-06-15 | Order → |
| Elmiron pentosan polysulfate sodium | bene-Arzneimittel GmbH | Cystitis, Interstitial | 🇪🇺 EU 2017-06-02 | Order → |
| Refixia nonacog beta pegol Additional monitoring | Novo Nordisk A/S | Hemophilia B | 🇪🇺 EU 2017-06-02 | Order → |
| Brineura cerliponase alfa OrphanExceptional circumstancesAccelerated assessment | BioMarin International Limited | Neuronal Ceroid-Lipofuscinoses | 🇪🇺 EU 2017-05-30 | Order → |
| Spinraza nusinersen OrphanAccelerated assessment | Biogen Netherlands B.V. | Muscular Atrophy, Spinal | 🇪🇺 EU 2017-05-30 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.